These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug act. Mechler K; Mountford WK; Hoffmann GF; Ries M Orphanet J Rare Dis; 2015 Apr; 10():46. PubMed ID: 25896727 [TBL] [Abstract][Full Text] [Related]
14. Drugs for rare diseases: mixed assessment in Europe. Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539 [TBL] [Abstract][Full Text] [Related]
15. [Therapy of lysosomal storage diseases: update and perspectives]. Lara-Aguilar RA; Juárez-Vázquez CI; Medina-Lozano C Rev Invest Clin; 2011; 63(6):651-8. PubMed ID: 23650678 [TBL] [Abstract][Full Text] [Related]
16. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
17. Therapies for inborn errors of metabolism: what has the orphan drug act delivered? Talele SS; Xu K; Pariser AR; Braun MM; Farag-El-Massah S; Phillips MI; Thompson BH; Coté TR Pediatrics; 2010 Jul; 126(1):101-6. PubMed ID: 20566615 [TBL] [Abstract][Full Text] [Related]
18. Emptying the stores: lysosomal diseases and therapeutic strategies. Platt FM Nat Rev Drug Discov; 2018 Feb; 17(2):133-150. PubMed ID: 29147032 [TBL] [Abstract][Full Text] [Related]
19. Treatment for LSDs: no longer just enzyme replacement therapy for Gaucher disease. Foreword. Cohen IJ; Baris H; Mistry PK Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():58. PubMed ID: 24380122 [No Abstract] [Full Text] [Related]
20. Current and emerging therapies for the lysosomal storage disorders. Pastores GM; Barnett NL Expert Opin Emerg Drugs; 2005 Nov; 10(4):891-902. PubMed ID: 16262569 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]